ABSTRACT
Background Statistical significance currently defines superiority in phase III oncology trials. However, this practice is increasingly questioned. Here, we estimated the fragility of phase III oncology trials.
Methods Using Kaplan-Meier curves for the primary endpoints of 230 two-arm superiority phase III oncology trials, we reconstructed data for individual patients. We estimated the survival-inferred fragility index (SIFI) by iteratively flipping the best responder from the experimental arm to the control arm (SIFIB) until the interpretation was changed according to the significance threshold of each trial. Severe fragility was defined by SIFI ≤1%.
Results This study included 230 trials enrolling 184,752 patients. The median number of patients required to change trial interpretation was 8 (interquartile range, 4 to 19) or 1.4% (interquartile range, 0.7% to 3%) per SIFIB. Estimations of SIFI by multiple methods were largely consistent. For trials with an overall survival primary endpoint, the median SIFIB was 1% (IQR, 0.5% to 1.9%). Severe fragility was found in 87 trials (38%). As a continuous statistic, the original P value—but not its binary significance interpretation—was associated with fragility and severe fragility. Trials with subsequent FDA approval had lower odds of severe fragility. Lastly, the underlying survival model had differential effects on SIFI estimation.
Conclusions Even among phase III oncology trials, which directly inform patient care, changes in the outcomes of few patients are often sufficient to change statistical significance and trial interpretation. These findings imply that current definitions of statistical significance used in phase III oncology are inadequate to identify replicable findings.
Competing Interest Statement
Alexander Sherry reports honoraria from Sermo. Pavlos Msaouel reports honoraria for scientific advisory board membership for Mirati Therapeutics, Bristol Myers Squibb, and Exelixis; consulting fees from Axiom Healthcare; non branded educational programs supported by DAVA Oncology, Exelixis, and Pfizer; leadership or fiduciary roles as a Medical Steering Committee Member for the Kidney Cancer Association and as a Kidney Cancer Scientific Advisory Board Member for KCCure; and research funding from Regeneron Pharmaceuticals, Takeda, Bristol Myers Squibb, Mirati Therapeutics, and Gateway for Cancer Research (all unrelated to this content). Zachary McCaw reports employment at Insitro (unrelated to this content). Tomer Meirson reports consulting fees from Purple Biotech. No other authors report any conflicts of interest.
Funding Statement
This work was supported in part by the National Institutes of Health National Cancer Institute through MD Anderson Cancer Center Support Grant P30CA016672. Pavlos Msaouel and Ethan Ludmir are recipients of the Andrew Sabin Family Foundation Fellowship.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos